Depression is a common feature of Parkinsons disease, with studies reporting a prevalence ranging from 25% to 45% (Ravina et al. Neurology 2007;69:342-347; Lemke et al. J Neurol Sci 2006;248:266-270). However, few randomized controlled trials of depression in PD have been performed and the optimal treatment approach has not been established.
Neurology
Stroke reduction with rosuvastatin: the Jupiter Study
March 24, 2009REPORT FROM THE AHA/ASA INTERNATIONAL STROKE CONFERENCE – Statin treatment significantly reduced the number of stroke events versus placebo, according to results from the JUPITER trial presented at the International Stroke Conference (Ridker et al. Abstract 140).
Read More
Adherence and outcomes in stroke
March 24, 2009REPORT FROM THE AHA/ASA INTERNATIONAL STROKE CONFERENCE – A retrospective analysis of data from the Vitamin Intervention for Stroke Prevention (VISP) trial has examined the impact of patient adherence on clinical outcomes (Ovbiagele et al. Abstract P466).
Read More
Inadequate ASA response common in secondary stroke prevention
March 24, 2009REPORT FROM THE AHA/ASA INTERNATIONAL STROKE CONFERENCE – Patients who do not respond to low-dose acetylsalicylic acid (ASA) for secondary stroke prevention are unlikely to respond to a higher dose, according to researchers at the University of Buffalo, NY (Gengo et al. Abstract 85).
Read More
Switching MS therapies effective after treatment failure
March 10, 2009
Leave a reply
For multiple sclerosis patients who fail to respond to a first-line disease-modifying treatment (DMT), switching to another DMT is a generally effective strategy, according to an analysis by U.S. and Italian researchers (Gajofatto et al. Mult Scler 2009;15:50-58).